Page 1

Amniotics Interim Report 3rd Quarter 2021 Preparing for clinical phase July - September in brief ● Total revenues : SEK 0 ( 0 ) thousand . Operating profit ( EBITDA ) : SEK -9,778 ( -5,437 ) thousand . Result for the period : SEK -10,211 ( -5,998 ) thousand . Earnings per share : SEK -0.64 ( -0.54 ) . Cash and cash equivalents at the end of the reporting period : SEK 54,158 ( 9,754 ) thousand . As a consequence of the exercise warrants series 2017/2021 and series 2018/2021 , the share capital increased by 204,500 shares and the proceeds to the company amounts to SEK 1,842 thousand . Equity / assets ratio as per the end of the reporting period : 92 ( 88 ) % . Nasdaq Stockholm approved trading of Amniotics shares and warrants on Nasdaq First North Growth Market and the first day of trading was 6 July 2021 . January - September in brief Total revenues : SEK 0 ( 0 ) thousand . Operating profit ( EBITDA ) : SEK -39,088 ( -15,782 ) thousand . Result for the period : SEK -40,380 ( -17,145 ) thousand . Earnings per share : SEK -2.55 ( -1.54 ) . Cash flow for the period : SEK 53,648 ( 3,727 ) thousand . In the second quarter Amniotics raised SEK 60 million for the Company before issue expenses in a rights issue . Events after the end of the reporting period Lars Stigsson , a member of the Board of Directors of Amniotics AB ( publ ) resigned from the Board of Directors of the company on 12 October 2021 . The members of the Nomination Committee were appointed and consists of : Christer Fåhraeus , Marcus Larsson , Lars Stigsson represented by Fredrik Tiberg and Peter Buhl Jensen , Chairman of the Board of Amniotics AB .